– UK, Nottingham – Scancell Holdings plc (LON: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announced the appointment of Dr. Florian Reinaud (MD) to its Board as a Non-Executive Director.
“I am pleased to welcome Florian to Scancell, where he will represent one of the Company’s key investors. His broad biopharmaceutical industry and financial experience, coupled with his strong relationships with the investment community and first-hand experience in the medical field, will be invaluable as we continue to advance our lead assets through later stage clinical development, and I am confident he will add significant value to the Company.” said Board Chairman, Dr. Jean-Michel Cosséry.
About Dr. Florian Reinaud
Dr. Reinaud is a highly accomplished life sciences professional who brings over 20 years of leadership and investment experience across established pharmaceutical companies, start-ups, and healthcare investment organizations. He is currently on the investment team at Redmile, an investment firm that focuses on the healthcare sector. Florian began his career as a medical doctor in the NHS before moving to Schroders Salomon Smith Barney, Citigroup’s European investment banking arm, working as an equity analyst covering the pan-European MedTech and healthcare services. He then transitioned to the healthcare team at Apax Partners in Paris, advising on and executing venture and late-stage investments.
Following his time at Apax, Partners, Dr. Reinaud became the first CFO of Paris-based DBV technologies, a biopharmaceutical specializing in allergy diagnosis and treatment, and then went on to serve as a Partner at CDC Innovation Capital, a French venture capital firm focused on investments in healthcare services, for six years. He later co-founded and served as CEO of Concilio, a medical concierge service, for six years, before joining Redmile.
Dr. Florian Reinaud holds a BA (Hons) in Physiology from Oxford University, as well as a medical degree from Imperial College London School of Medicine.
About Scancell
Scancell is a clinical-stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognize damaged or infected cells. To destroy such cancerous or infected cells, Scancell uses either a vaccine to induce immune responses or monoclonal antibodies to redirect immune cells or drugs. The Company’s unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines, this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and/or lipids or enhances the potency of antibodies and their ability to directly kill tumor cells.
For more: https://www.scancell.co.uk
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.